Oncotarget

Research Papers:

Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China

Shi-Qiang Qu, Tie-Jun Qin, Ze-Feng Xu, Yue Zhang, Xiao-Fei Ai, Bing Li, Hong-Li Zhang, Li-Wei Fang, Li-Juan Pan, Nai-Bo Hu and Zhi-Jian Xiao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:33229-33236. https://doi.org/10.18632/oncotarget.8906

Metrics: PDF 1868 views  |   HTML 2090 views  |   ?  


Abstract

Shi-Qiang Qu1,2, Tie-Jun Qin1, Ze-Feng Xu1,2, Yue Zhang1,2, Xiao-Fei Ai3, Bing Li1,2, Hong-Li Zhang1, Li-Wei Fang1, Li-Juan Pan1, Nai-Bo Hu1, Zhi-Jian Xiao1,2

1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

2State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

3Molecular Diagnostic Laboratory, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Correspondence to:

Zhijian Xiao, email: zjxiao@hotmail.com

Keywords: eosinophilia, FIP1L1-PDGFRA, chronic eosinophilic leukemia, imatinib

Received: February 23, 2016     Accepted: April 03, 2016     Published: April 21, 2016

ABSTRACT

Background: The FIP1L1/PDGFRA (F/P) fusion gene is the most common clonal genetic abnormality of chronic eosinophilic leukemia (CEL). Tyrosine kinase inhibitors (TKI), such as imatinib, have been demonstrated to be effective therapies for F/P mutated disease. The aim of this study was to analyze the treatment response and long term prognosis in patients with F/P mutated CEL.

Methods: The clinical features and treatment responses of 33 consecutive patients with F/P mutated CEL between August 2006 and October 2014 were analyzed. The 33 cases received imatinib therapy at an initial dose of 100 mg/day (30 patients) or 200 mg/day (3 patients); the maintenance dose depended on the response condition and patient willingness. Through the follow up, the molecular responses were regularly monitored.

Results: With a median follow up of 64 months, 94% of the 33 patients with F/P mutated CEL achieved a complete hematologic remission (CHR), and 97% achieved a complete molecular remission (CMR) after a median of 3 (1.5-12) months. Twenty-four cases received maintenance therapy, with a median CMR duration of 43 (5-88) months. Imatinib therapy was discontinued in 8 cases, including 4 cases who experienced relapse, and 4 patients who maintained CHR or CMR after discontinuing therapy with a median time of 47 (2-74) months. One case exhibited primary resistance with a PDGFRA T674I mutation.

Conclusions: F/P mutated CEL has an excellent long-term prognosis following imatinib therapy. A 100 mg daily dose of imatinib is sufficient to induce remission, and a single 100 mg weekly dose maintains a durable remission. A subgroup of patients may maintain a durable remission after discontinuing therapy with a CMR.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8906